Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT06686628
- Locations
- 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Karuna Therapeutics
- Target Recruit Count
- 78
- Registration Number
- NCT06605950
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Local Institution - 0002, Anaheim, California, United States
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 134
- Registration Number
- NCT06562907
- Locations
- 🇺🇸
ICON, Salt Lake City, Utah, United States
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06494761
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
- Conditions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT06383338
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06378398
- Locations
- 🇺🇸
The University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT06322706
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 122
- Registration Number
- NCT06279234
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06162169
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 369
- Registration Number
- NCT06114836
- Locations
- 🇺🇸
Nationwide Children's Hospita, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.